Cell proliferation of transitional cell bladder tumours determined by PCNA/cyclin immunostaining and its prognostic value
1992

Cell Proliferation in Bladder Cancer and Its Prognostic Value

Sample size: 178 publication Evidence: moderate

Author Information

Author(s): P.K. Lipponen, M.J. Eskelinen

Primary Institution: University of Kuopio, Finland

Hypothesis

The study aims to assess the fraction of proliferating cells in transitional cell bladder cancer (TCC) using PCNA/cyclin immunostaining and correlate the findings to clinical outcomes.

Conclusion

The growth fraction determined by PCNA/cyclin immunostaining is a significant prognostic variable in transitional cell bladder cancer.

Supporting Evidence

  • The fraction of PCNA/cyclin positive nuclei was related to T-category, papillary status, WHO grade, DNA ploidy, S phase fraction, and M/V index.
  • TCCs with pelvic lymph node metastasis had a significantly higher growth fraction than those confined to the bladder wall.
  • The fraction of PCNA/cyclin positive nuclei predicted progression in T-, N-, and M-categories.
  • In survival analysis, the fraction of PCNA/cyclin positive nuclei predicted survival in the entire cohort and in Ta-TI tumours.

Takeaway

This study looked at how fast bladder cancer cells grow and found that faster-growing cells are linked to worse outcomes for patients.

Methodology

The study analyzed 178 patients with newly diagnosed primary TCC treated at Kuopio University Hospital, using PCNA/cyclin immunostaining to assess cell proliferation and correlating it with clinical factors over a mean follow-up of 10 years.

Limitations

The study was limited to a single institution and may not be generalizable to other populations.

Participant Demographics

Patients aged 26-84 years, with a female/male ratio of 36/142.

Statistical Information

P-Value

P<0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication